Whitehawk Therapeutics, Inc. also files under AADI, ARPO; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Dalal Anupam | Director | Grant(A) | 38K | — | $0 |
| Jun 12, 2026 | Zhao Baiteng | Director | Grant(A) | 38K | — | $0 |
| Jun 12, 2026 | Maroun Richard E | Director | Grant(A) | 38K | — | $0 |
| Jun 12, 2026 | Aghazadeh Behzad | Director, 10% Owner | Grant(A) | 38K | — | $0 |
| Jun 12, 2026 | Reeve Emma | Director | Grant(A) | 38K | — | $0 |
| Jun 12, 2026 | Hirmand Mohammad | Director | Grant(A) | 38K | — | $0 |
| Jun 12, 2026 | Castelein Caley | Director | Grant(A) | 38K | — | $0 |
| Jun 12, 2026 | Desai Neil | Director | Grant(A) | 38K | — | $0 |
| May 14, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Grant(A) | 38K | $3.92 | $150K |
| May 14, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Grant(A) | 51K | $3.92 | $200K |
| May 14, 2026 | Dugan Margaret | Chief Medical Officer | Grant(A) | 19K | $3.92 | $75K |
| May 14, 2026 | Ball Bryan | See remarks | Grant(A) | 51K | $3.92 | $200K |
| May 14, 2026 | Castelein Caley | Director | Grant(A) | 2.1M | $8,124,996.24as filed | — |
| May 14, 2026 | Castelein Caley | Director | Grant(A) | 255K | $3.92 | $1000K |
| May 14, 2026 | Dalal Anupam | Director | Grant(A) | 1.3M | $3.92 | $5.0M |
| May 12, 2026 | Avoro Capital Advisors LLC | Director, 10% Owner | Grant(A) | 6.4M | $3.92 | $25.0M |
| Apr 16, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Sell(S) | 142K | $4.13 | $585K |
| Apr 15, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Sell(S) | 77K | $3.86 | $297K |
| Apr 14, 2026 | Ball Bryan | See remarks | Sell(S) | 92K | $3.64 | $337K |
| Apr 13, 2026 | Ball Bryan | See remarks | Sell(S) | 26K | $3.46 | $91K |
| Apr 10, 2026 | Ball Bryan | See remarks | Sell(S) | 7K | $3.43 | $23K |
| Apr 9, 2026 | Ball Bryan | See remarks | Sell(S) | 50K | $3.57 | $179K |
| Apr 9, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 15K | $3.38 | $49K |
| Apr 8, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 64K | $3.40 | $217K |
| Apr 7, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 94K | $3.43 | $323K |
| Apr 6, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 102K | $3.51 | $359K |
| Apr 2, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 27K | $3.48 | $93K |
| Apr 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 776K | — | $0 |
| Apr 1, 2026 | Dugan Margaret | Chief Medical Officer | Grant(A) | 283K | — | $0 |
| Apr 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Option exercise(M) | 474K | — | $0 |
| Apr 1, 2026 | Ball Bryan | See remarks | Grant(A) | 250K | — | $0 |
| Apr 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 776K | — | — |
| Apr 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Grant(A) | 831K | — | $0 |
| Apr 1, 2026 | Dornan David | Chief Scientific Officer | Grant(A) | 282K | — | $0 |
| Apr 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Grant(A) | 301K | — | $0 |
| Apr 1, 2026 | Ball Bryan | See remarks | Option exercise(M) | 367K | — | $0 |
| Apr 1, 2026 | Ball Bryan | See remarks | Option exercise(M) | 367K | — | — |
| Apr 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Option exercise(M) | 474K | — | — |
| Mar 2, 2026 | Ball Bryan | See remarks | Sell(S) | 2K | $3.31 | $6K |
| Mar 2, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Sell(S) | 3K | $3.31 | $9K |
| Mar 2, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 5K | $3.31 | $17K |
| Mar 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 16K | — | — |
| Mar 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Option exercise(M) | 7K | — | $0 |
| Mar 1, 2026 | Ball Bryan | See remarks | Option exercise(M) | 5K | — | $0 |
| Mar 1, 2026 | Ball Bryan | See remarks | Option exercise(M) | 5K | — | — |
| Mar 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Option exercise(M) | 7K | — | — |
| Mar 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 16K | — | $0 |
| Dec 1, 2025 | Dugan Margaret | Chief Medical Officer | Grant(A) | 55K | — | $0 |
| Dec 1, 2025 | Dugan Margaret | Chief Medical Officer | Grant(A) | 650K | — | $0 |
| Jun 17, 2025 | Zhao Baiteng | Director | Grant(A) | 40K | — | $0 |
| Jun 12, 2025 | Desai Neil | Director | Grant(A) | 40K | — | $0 |
| Jun 12, 2025 | Hirmand Mohammad | Director | Grant(A) | 40K | — | $0 |
| Jun 12, 2025 | Maroun Richard E | Director | Grant(A) | 40K | — | $0 |
| Jun 12, 2025 | Reeve Emma | Director | Grant(A) | 40K | — | $0 |
| Jun 12, 2025 | Castelein Caley | Director | Grant(A) | 40K | — | $0 |
| Jun 12, 2025 | Dalal Anupam | Director | Grant(A) | 40K | — | $0 |
| Jun 12, 2025 | Avoro Ventures LLC | Director, 10% Owner | Grant(A) | 40K | — | $0 |
| Apr 1, 2025 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Grant(A) | 474K | — | $0 |
| Apr 1, 2025 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Grant(A) | 474K | — | $0 |
| Apr 1, 2025 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Grant(A) | 776K | — | $0 |
| Apr 1, 2025 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Grant(A) | 776K | — | $0 |
| Apr 1, 2025 | Ball Bryan | See remarks | Grant(A) | 367K | — | $0 |
| Apr 1, 2025 | Ball Bryan | See remarks | Grant(A) | 367K | — | $0 |
| Mar 4, 2025 | Dalal Anupam | Director | Grant(A) | 1.6M | $2.40 | $3.7M |
| Mar 4, 2025 | Castelein Caley | Director | Grant(A) | 1.7M | $2.40 | $4.0M |
| Mar 4, 2025 | Zhao Baiteng | Director | Grant(A) | 1.3M | $2.40 | $3.0M |
| Mar 4, 2025 | Dornan David | Chief Scientific Officer | Grant(A) | 688K | — | $0 |
| Mar 4, 2025 | Ball Bryan | See remarks | Grant(A) | 100K | $2.40 | $240K |
| Mar 3, 2025 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Sell(S) | 3K | $2.35 | $7K |
| Mar 3, 2025 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 6K | $2.35 | $13K |
| Mar 3, 2025 | Ball Bryan | See remarks | Sell(S) | 2K | $2.35 | $5K |
| Mar 1, 2025 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Option exercise(M) | 7K | — | — |
| Mar 1, 2025 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 16K | — | $0 |
| Mar 1, 2025 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 16K | — | — |
| Mar 1, 2025 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | Option exercise(M) | 7K | — | $0 |
| Mar 1, 2025 | Ball Bryan | See remarks | Option exercise(M) | 5K | — | $0 |
| Mar 1, 2025 | Ball Bryan | See remarks | Option exercise(M) | 5K | — | — |
| Feb 28, 2025 | Aghazadeh Behzad | Director, 10% Owner | Grant(A) | 8.3M | $2.40 | $20.0M |
| Dec 19, 2024 | Zhao Baiteng | Director | Grant(A) | 61K | — | $0 |
| Oct 3, 2024 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Sell(S) | 10K | $1.94 | $19K |
| Oct 2, 2024 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 33K | — | $0 |
| Oct 2, 2024 | Lennon David James | CHIEF EXECUTIVE OFFICER, Director | Option exercise(M) | 33K | — | $0 |
| Sep 3, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 40K | $1.71 | $68K |
| Aug 5, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 6K | $1.34 | $8K |
| Aug 2, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 19K | $1.41 | $27K |
| Aug 1, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 15K | $1.50 | $23K |
| Jul 2, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 9K | $1.34 | $12K |
| Jul 1, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 31K | $1.45 | $45K |
| Jun 12, 2024 | Hehenberger Karin M. | Director | Grant(A) | 46K | — | $0 |
| Jun 12, 2024 | Maroun Richard E | Director | Grant(A) | 46K | — | $0 |
| Jun 12, 2024 | Reeve Emma | Director | Grant(A) | 46K | — | $0 |
| Jun 12, 2024 | Avoro Capital Advisors LLC | Director, 10% Owner | Grant(A) | 46K | — | $0 |
| Jun 12, 2024 | Castelein Caley | Director | Grant(A) | 46K | — | $0 |
| Jun 12, 2024 | Hirmand Mohammad | Director | Grant(A) | 46K | — | $0 |
| Jun 12, 2024 | Dalal Anupam | Director | Grant(A) | 46K | — | $0 |
| Jun 4, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 20K | $1.77 | $36K |
| Jun 3, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 20K | $1.81 | $36K |
| May 1, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 40K | $1.93 | $77K |
| Apr 2, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 22K | $2.23 | $50K |
| Apr 1, 2024 | Desai Neil | EXECUTIVE CHAIRMAN, Director | Sell(S) | 18K | $2.31 | $41K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Whitehawk Therapeutics, Inc., SEC CIK 0001422142. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under WHWK and shows every filing by that issuer (also filed as AADI, ARPO).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-05. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for WHWK